|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2010-11-12
|
|
pubmed:abstractText |
the aim of this study was to determine whether telmisartan decreases all-cause and cardiovascular mortality and morbidity in hemodialysis patients with chronic heart failure (CHF) and impaired left ventricular ejection fraction (LVEF) when added to standard therapies with angiotensin-converting enzyme inhibitors.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1558-3597
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
16
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1701-8
|
|
pubmed:dateRevised |
2011-7-5
|
|
pubmed:meshHeading |
pubmed-meshheading:21070920-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:21070920-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:21070920-Benzimidazoles,
pubmed-meshheading:21070920-Benzoates,
pubmed-meshheading:21070920-Dose-Response Relationship, Drug,
pubmed-meshheading:21070920-Double-Blind Method,
pubmed-meshheading:21070920-Drug Therapy, Combination,
pubmed-meshheading:21070920-Female,
pubmed-meshheading:21070920-Follow-Up Studies,
pubmed-meshheading:21070920-Heart Failure,
pubmed-meshheading:21070920-Humans,
pubmed-meshheading:21070920-Italy,
pubmed-meshheading:21070920-Length of Stay,
pubmed-meshheading:21070920-Male,
pubmed-meshheading:21070920-Middle Aged,
pubmed-meshheading:21070920-Morbidity,
pubmed-meshheading:21070920-Prospective Studies,
pubmed-meshheading:21070920-Renal Dialysis,
pubmed-meshheading:21070920-Survival Rate,
pubmed-meshheading:21070920-Time Factors,
pubmed-meshheading:21070920-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.
|
|
pubmed:affiliation |
Second University of Naples, Naples, Italy. gennarocice@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|
